Revenue for Q3 FY18 of INR 2,063 Million, a growth of 17% (y-o-y) and for 9M FY18 of INR 6,084 Million, a growth of 17.5% (y-o-y)
EBITDA for Q3 FY18 at INR 319 Million, a growth of 15.3% (yo-y) and for 9M FY18 of INR 968 Million, a growth of 19.4% (y-o-y)
Bengaluru, February 09, 2018: HealthCare Global Enterprises Limited (“HCG”) today announced its financial results for the quarter (“Q3 FY18”) and nine months (“9M FY18”) ended December 31, 2017.
Highlights for quarter ended December 31st, 2017
INR million except earnings per share
Period Ended Dec 31 | Q3-FY18 | Q3-FY17 | Growth (y-o-y) | YTD-FY18 | YTD-FY17 | Growth (y-o-y) | |
Income from Operations | 2,063 | 1,762 | 17.1% | 6,084 | 5,177 | 17.5% | |
Other Income | 59 | 17 | 102 | 61 | |||
EBITDA(1) | 319 | 277 | 15.3% | 968 | 811 | 19.4% | |
EBITDA Margin (%) | 15.1% | 15.6% | 15.7% | 15.5% | |||
Operating EBITDA(2) | 261 | 260 | 0.3% | 866 | 750 | 15.5% | |
EBITDA Margin (%) | 12.6% | 14.8% | 14.2% | 14.5% | |||
PBT(3) | 35 | 77 | -54.4% | 250 | 232 | 8.1% | |
PBT Margin (%) | 1.7% | 4.4% | 4.1% | 4.5% | |||
PAT(4) | 32 | 54 | -40.4% | 179 | 153 | 17.4% | |
PAT Margin (%) | 1.5% | 3.0% | 2.9% | 2.9% | |||
Earnings Per Share | 0.37 | 0.62 | -40.3% | 2.09 | 1.79 | 16.8% |
Profit before depreciation and amortization, finance costs, exceptional items and taxes
Business Updates for Q3 FY18
Commenting on the results, Dr. B.S. Ajaikumar, Chairman and CEO, HealthCare Global Enterprises Ltd. said, “We are pleased to report Q3 FY18 results with consistent performance in a changing healthcare landscape. We welcome the announcement from the government which will potentially make high quality healthcare accessible to 500mn people. HCG given our strong presence in Tier 2 and Tier 3 cities across India through our oncology care network is very well positioned in this new landscape. Also, we are very excited about the prospects of the newest addition to the HCG Family – created from the business combination of our Triesta unit with Strand Life Sciences – to create India’s leading speciality diagnostics company. This will redefine precision medicine with end to end expertise spanning bioinformatics, genomics and research. We feel our focused approach in cancer care and fertility treatment, positions us well for the future.”
Earnings Call
The company will conduct a one hour conference call at 5:00 PM IST on Thursday February 8, 2018 where the management will discuss insights about the company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is +91 22 3938 1009 / +91 7045671221. Other numbers are listed in the conference call invite which is uploaded on the stock exchange and posted on our website.
Corporate Comm India(CCI Newswire)
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…